In this week's edition...
 
-- Opportunity: Sign an Open Letter Rejecting Use of QALYs and Similar Measures. See details below.
— National Minority Quality Forum Issue Brief Details MFN Consequences. Click here to read the issue brief.
— Patient Groups Call Attention to Payer’s Discriminatory Policy. Click here to read the letter.
— Report: Foreign Countries Rely on Flawed and Outdated HTA or Value Assessment Methods. Click here to read the report.
— Update on the Texas v. Kennedy Lawsuit. See details below.
— Follow the Medicaid Debate. See details below.
— CMS References ICER and NICE in Explanations for Medicare Drug Price Negotiation Program. See details below.
— Learn More About Alternative Measures for Value Assessment. Click here to learn more.
— Emerging Threats in States for Use of Discriminatory Metrics. See details below.
— What Happens in Countries Using QALYs and Cost-Based Thresholds? See details below.
— ICER's QALY-Based Study Topics. See details below.
— Upcoming Events and Webinars. See details below.
— AHRQ Effective Program Updates. See details below.

In this week's edition...

— Another Threat to Medicaid & Medicare: Tell Policymakers to Avoid Modeling Countries that Ration Care, Devalue Disability. See details below.
— National Minority Quality Forum Issue Brief Details MFN Consequences. Click here to read the issue brief.
— PCORI Offers Scholarships for Patients, Caregivers, and PCORI Ambassadors. See details below.
— Patient Groups Call Attention to Payer’s Discriminatory Policy. Click here to read the letter.
— Report: Foreign Countries Rely on Flawed and Outdated HTA or Value Assessment Methods. Click here to read the report.
— Update on the Texas v. Kennedy Lawsuit. See details below.
— Follow the Medicaid Debate. See details below.
— CMS References ICER and NICE in Explanations for Medicare Drug Price Negotiation Program. See details below.
— Learn More About Alternative Measures for Value Assessment. Click here to learn more.
— Emerging Threats in States for Use of Discriminatory Metrics. See details below.
— What Happens in Countries Using QALYs and Cost-Based Thresholds? See details below.
— ICER's QALY-Based Study Topics. See details below.
— Upcoming Events and Webinars. See details below.

In this week's edition...
 
— PIPC Calls on Policymakers to Avoid Devaluing Patients, People with Disabilities and Older Adults, Modeling Countries that Ration Care. See details below.
— National Minority Quality Forum Issue Brief Details MFN Consequences. Click here to read the issue brief.
— PIPC to Hold a Webinar on Protecting Patient Access in Nevada. See details below.
— Make Your Voice Heard in the Oregon PDAB. Click here to watch the video.
— Patient Groups Call Attention to Payer’s Discriminatory Policy. Click here to read the letter.
— Report: Foreign Countries Rely on Flawed and Outdated HTA or Value Assessment Methods. Click here to read the report.
— Update on the Texas v. Kennedy Lawsuit. See details below.
— Maryland Matters: It’s Time to Hit Pause on the PDAB. See details below.
— CMS References ICER and NICE in Explanations for Medicare Drug Price Negotiation Program. See details below.
-- Learn More About Alternative Measures for Value Assessment. Click here to learn more.
— Emerging Threats in States for Use of Discriminatory Metrics. See details below.
— What Happens in Countries Using QALYs and Cost-Based Thresholds? See details below.
— ICER's QALY-Based Study Topics. See details below.
— Upcoming Events and Webinars. See details below.
— AHRQ Effective Program Updates. See details below.

​The Partnership to Improve Patient Care (PIPC) has issued the following statement calling on the Trump administration to avoid policies that discriminate against patients and people with disabilities. 

In this week's edition...​

— PIPC Calls on Policymakers to Avoid Devaluing Patients, People with Disabilities and Older Adults. See details below.

— Make Your Voice Heard in the Oregon PDAB. Click here to watch the video.

— Patient Groups Call Attention to Payer’s Discriminatory Policy. Click here to read the letter.

— Report: Foreign Countries Rely on Flawed and Outdated HTA or Value Assessment Methods. Click here to read the report.

— Update on the Texas v. Kennedy Lawsuit. See details below.

— Maryland Matters: It’s Time to Hit Pause on the PDAB. See details below.

— Use of QALYs and Similar Measures Deemed Acceptable in MD, Considered in Congress. See details below.

— The Protecting Health Care for All Patients Act Has No Budget Impact. See details below.

— CMS References ICER and NICE in Explanations for Medicare Drug Price Negotiation Program. See details below.

-- Learn More About Alternative Measures for Value Assessment. Click here to learn more.

— Emerging Threats in States for Use of Discriminatory Metrics. See details below.

— What Happens in Countries Using QALYs and Cost-Based Thresholds? See details below.

— ICER's QALY-Based Study Topics. See details below

— Upcoming Events and Webinars. See details below

— AHRQ Effective Program Updates. See details below.

The Partnership to Improve Patient Care (PIPC) has issued the following statement calling on the Trump administration to avoid policies that discriminate against patients and people with disabilities. 

In this week's edition...
 
— Update on the Texas v. Kennedy Lawsuit. See details below.
— Patient Groups Call Attention to Payer’s Discriminatory Policy. Click here to read the letter.
— WATCH: Making Your Voice Heard in the Oregon PDAB. Click here to watch the video.
— Learn How PCORnet® Resources Power Patient-Centered Kidney Research. Click here to read the brief.
— Maryland Matters: It’s Time to Hit Pause on the PDAB. See details below.
— Patient, Caregiver and Patient Advocate Self-Nominations Invited for PQA Health Plan Measure Concept Advisory Group. See details below.
— Payer Perspectives Confirm UPLs Will Likely Raise Costs and Hinder Patient Access to Medicines. Click here to read the survey.
— CMS Public Engagement Events for Medicare Drug Negotiation Program. See details below.
— Use of QALYs and Similar Measures Deemed Acceptable in MD, Considered in Congress. See details below.
— The Protecting Health Care for All Patients Act Has No Budget Impact. See details below.
— CMS References ICER and NICE in Explanations for Medicare Drug Price Negotiation Program. See details below.
— Learn More About Alternative Measures for Value Assessment. Click here to learn more.
— Emerging Threats in States for Use of Discriminatory Metrics. See details below.
— What Happens in Countries Using QALYs and Cost-Based Thresholds? See details below.
— ICER's QALY-Based Study Topics. See details below.
— Upcoming Events and Webinars. See details below.
— AHRQ Effective Program Updates. See details below.

In this week's edition...
 
— TODAY! Oregon Advocate Meeting: Drug Affordability Review Process Updates. See details below.
— Maryland Matters: It’s Time to Hit Pause on the PDAB. Click here to read the op-ed.
— Community Sign On Letter - IBX Policy Excluding Coverage for Rare Disease Products. See details below.
— Patient, Caregiver and Patient Advocate Self-Nominations Invited for PQA Health Plan Measure Concept Advisory Group. See details below.
— Payer Perspectives Confirm UPLs Will Likely Raise Costs and Hinder Patient Access to Medicines. Click here to read the survey.
— CMS Public Engagement Events for Medicare Drug Negotiation Program. See details below.
— Use of QALYs and Similar Measures Deemed Acceptable in MD, Considered in Congress. See details below.
— The Protecting Health Care for All Patients Act Has No Budget Impact. See details below.
— CMS References ICER and NICE in Explanations for Medicare Drug Price Negotiation Program. See details below.
-- Learn More About Alternative Measures for Value Assessment. Click here to learn more.
— Emerging Threats in States for Use of Discriminatory Metrics. See details below.
— What Happens in Countries Using QALYs and Cost-Based Thresholds? See details below.
— ICER's QALY-Based Study Topics. See details below.
— Upcoming Events and Webinars. See details below.
— AHRQ Effective Program Updates. See details below.

In this week's edition...
 
— Oregon Advocate Meeting: Drug Affordability Review Process Updates. See details below.
— Payer Perspectives Confirm UPLs Will Likely Raise Costs and Hinder Patient Access to Medicines. Click here to read the survey.
— New PCORnet Data Report Provides Insights on Patient Populations Receiving Gene Therapy. Click here to read the report.
— CMS Public Engagement Events for Medicare Drug Negotiation Program. Click here to read the report.
— Use of QALYs and Similar Measures Deemed Acceptable in MD, Considered in Congress. See details below.
— The Protecting Health Care for All Patients Act Has No Budget Impact. See details below.
— CMS References ICER and NICE in Explanations for Medicare Drug Price Negotiation Program. See details below.
— ICHOM Conference and Activities Geared Up for 2025. See details below.
— Learn More About Alternative Measures for Value Assessment. Click here to learn more.
— Emerging Threats in States for Use of Discriminatory Metrics. See details below.
— What Happens in Countries Using QALYs and Cost-Based Thresholds? See details below.
— ICER's QALY-Based Study Topics. See details below.
— Upcoming Events and Webinars. See details below.
— AHRQ Effective Program Updates. See details below

In this week's edition...
 
— PCORI Engagement Award Letters of Intent Due Tomorrow! See details below.
— Centering Caregivers in Rare Disease: Elevating Their Role in Patient-Centered Research. Click here to read the post.
— MedPage Today: Patient Safety Research May Be Imperiled if AHRQ Is Downsized. Click here to read the article.
— CMS Public Engagement Events for Medicare Drug Negotiation Program. See details below.
— Use of QALYs and Similar Measures Deemed Acceptable in MD, Considered in Congress. See details below.
— The Protecting Health Care for All Patients Act Has No Budget Impact. See details below.
— CMS References ICER and NICE in Explanations for Medicare Drug Price Negotiation Program. See details below.
— ICHOM Conference and Activities Geared Up for 2025. See details below.
— Learn More About Alternative Measures for Value Assessment. Click here to learn more.
— Emerging Threats in States for Use of Discriminatory Metrics. See details below.
— What Happens in Countries Using QALYs and Cost-Based Thresholds? See details below.
— ICER's QALY-Based Study Topics. See details below.
— Upcoming Events and Webinars. See details below.
— AHRQ Effective Program Updates. See details below.

In this week's edition...
​
— CMS Public Engagement Events for Medicare Drug Negotiation Program. See details below.
— ICHOM Conference and Activities Geared Up for 2025. See details below.
— QALY Impact in Canada: Local Family Struggled to Find Treatment, Financing for Rare Disease. Click here to read more.
— Use of QALYs and Similar Measures Deemed Acceptable in MD, Considered in Congress. See details below.
— The Protecting Health Care for All Patients Act Has No Budget Impact. See details below.
— CMS References ICER and NICE in Explanations for Medicare Drug Price Negotiation Program. See details below.
— Learn More About Alternative Measures for Value Assessment. Click here to learn more.
— PCORI Engagement Award Letters of Intent Due April 1! See details below.
— Emerging Threats in States for Use of Discriminatory Metrics. See details below.
— What Happens in Countries Using QALYs and Cost-Based Thresholds? See details below.
— ICER's QALY-Based Study Topics. See details below.
— Upcoming Events and Webinars. See details below.
— AHRQ Effective Program Updates. See details below

In this week's edition...
 
— CMS Public Engagement Events for Medicare Drug Negotiation Program. See details below.
— ICHOM Conference and Activities Geared Up for 2025. See details below.
— QALY Impact in Canada: Local Family Struggled to Find Treatment, Financing for Rate Disease. Click here to read more.
— Use of QALYs and Similar Measures Deemed Acceptable in MD, Considered in Congress. See details below.
— The Protecting Health Care for All Patients Act Has No Budget Impact. See details below.
— CMS References ICER and NICE in Explanations for Medicare Drug Price Negotiation Program. See details below.
— Learn More About Alternative Measures for Value Assessment. Click here to learn more.
— PCORI Engagement Award Letters of Intent Due April 1! See details below.
— Emerging Threats in States for Use of Discriminatory Metrics. See details below.
— What Happens in Countries Using QALYs and Cost-Based Thresholds? See details below.
— ICER's QALY-Based Study Topics. See details below.
— Upcoming Events and Webinars. See details below.
— AHRQ Effective Program Updates. See details below

In this week's edition...
 
— CMS Public Engagement Events for Medicare Drug Negotiation Program. See details below.
— Use of QALYs and Similar Measures Deemed Acceptable in MD, Considered in Congress. See details below.
— The Protecting Health Care for All Patients Act Has No Budget Impact. See details below.
— CMS References ICER and NICE in Explanations for Medicare Drug Price Negotiation Program. See details below.
— Learn More About Alternative Measures for Value Assessment. Click here to learn more.
— PCORI Engagement Award Letters of Intent Due April 1! See details below.
— Emerging Threats in States for Use of Discriminatory Metrics. See details below.
— What Happens in Countries Using QALYs and Cost-Based Thresholds? See details below.
— ICER's QALY-Based Study Topics. See details below.
— Upcoming Events and Webinars. See details below.
— AHRQ Effective Program Updates. See details below.

In this week's edition...
 
— CMS Public Engagement Events for Medicare Drug Negotiation Program. See details below.
— Use of QALYs and Similar Measures Deemed Acceptable in MD, Considered in Congress. See details below.
— The Protecting Health Care for All Patients Act Has No Budget Impact. See details below.
— CMS References ICER and NICE in Explanations for Medicare Drug Price Negotiation Program. See details below.
— Learn More About Alternative Measures for Value Assessment. Click here to learn more.
— PCORI Engagement Award Letters of Intent Due April 1! See details below.
— Join PCORI's Advisory Panels: Applications, Nominations are Due this Friday, March 7! Click here for additional details and to submit an application.
— Emerging Threats in States for Use of Discriminatory Metrics. See details below.
— What Happens in Countries Using QALYs and Cost-Based Thresholds? See details below.
— ICER's QALY-Based Study Topics. See details below.
— Upcoming Events and Webinars. See details below.
— AHRQ Effective Program Updates. See details below.​